window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 15, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

hospitalisation

  • Chronic diseases,Clinical Development,Clinical studies,Drug Development,Drug discovery,Gastroenterology,Immunology,Pharmaceuticals and therapeutics

    Patients with Crohn’s disease maintain steroid-free remission for three years with Lilly’s Omvoh (mirikizumab)

    Long-term VIVID-2 data show more than 90% of patients with [...]

    February 19, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • William Blair highlights Carterra as key player in AI-driven drug discovery shift
    Categories: Artificial Intelligence, Drug Development, Drug discovery, Research & Development, Technology and platforms
  • 23andMe study links genetics to GLP-1 weight loss outcomes and side effects
    Categories: Artificial Intelligence, Clinical Development, Genomics and sequencing, Obesity, Precision medicine, Technology and platforms
  • Life Biosciences raises $80M to advance gene therapy for optic neuropathies
    Categories: Clinical Trials, Funding, Opthalmology, Pharmaceuticals and therapeutics, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top